TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19509020
Drug: High-dose cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cortisol infusion (twofold greater elevations of plasma cortisol)
Study: 19509020
Drug: Hypoglycemic clamps
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic clamps (2.9 mmol/l)
Study: 19509020
Drug: Euglycemic clamps
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic clamps (5.1 mmol/l)
Study: 10093945
Drug: Ofloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (10 mg/kg/day in two divided doses for 5 days)
Study: 10093945
Drug: Cefixime (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (20 mg/kg/day in two divided doses for 7 days)
Study: 7486178
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (0.15, 0.45, 1.5 ppm)
Study: 7486178
Drug: Intravenous almitrine
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous almitrine (16 micrograms.kg-1.min-1)
Study: 7486178
Drug: Almitrine plus
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine plus inhaled nitric oxide (1.5 ppm)
Study: 2030370
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day tetrahydroaminoacridine (THA) and 10 g/day lecithin
Study: 7044195
Drug: Fluocortin butylester
Normalized name: fluocortin
DrugBank: Fluocortin (DB13223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortin butylester (FCB) 4 mg
Study: 31846014
Drug: Rocuronium (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (1.2 mg/kg)
Study: 19387176
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg/kg)
Study: 28705122
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application with active reminders of oral hygiene (3 times a day)
Study: 28705122
Drug: Verbal oral
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal oral hygiene instructions
Study: 16550733
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg b.i.d. for 7 days plus norethisterone and ethinyl estradiol on Day 7
Study: 16550733
Drug: OrthoNovum containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OrthoNovum containing 1 mg norethisterone and 35 microg ethinyl estradiol
Study: 10880410
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg per day)
Study: 9234037
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg/70 kg)
Study: 9234037
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg/70 kg)
Study: 9234037
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg/70 kg)
Study: 9234037
Drug: Alprazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.5 mg/70 kg)
Study: 9234037
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Study: 9234037
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Study: 9234037
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Study: 9234037
Drug: Alprazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.5 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Study: 9234037
Drug: Ethanol (0‐0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0‐0.6 g/kg)
Study: 3980799
Drug: Suberythemogenic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suberythemogenic doses of ultraviolet B (UVB) radiation with tar oil
Study: 11754126
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (IV CMI) 25 mg increasing to 250 mg by day 10, continuing to day 14
Study: 11754126
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (IV CMI)
Study: 8514538
Drug: Topical ascorbic
Normalized name: ascorbic acid Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ascorbic acid solution applied twice per day during radiotherapy
Study: 8514538
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) applied twice per day during radiotherapy
Study: 28704584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of solifenacin 5 mg + mirabegron 25 mg
Study: 28704584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of solifenacin 5 mg + mirabegron 50 mg
Study: 17989547
Drug: Rehydration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehydration with approximately 1 l fluid for minor surgical procedures; 1-3 l fluid for moderate surgical procedures (laparoscopic surgery)
Study: 17989547
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a carbohydrate-rich beverage preoperatively
Study: 15891265
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) given twice daily for 14 days
Study: 15891265
Drug: Nizatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (150 mg) given twice daily for 14 days
Study: 27322159
Drug: Twice-weekly peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly peer play psychotherapy (PPP)
Study: 27322159
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage of PPP
Study: 25640290
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone
Study: 15454247
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for advanced disease
Study: 15454247
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for colorectal cancer
Study: 27343685
Drug: hf-tRNS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: hf-tRNS with no concurrent training
Study: 24636027
Drug: Povidone-iodine soaks
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine soaks 3 times daily
Study: 24636027
Drug: Daily dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dressing changes
Study: 19205545
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg daily
Study: 18175337
Drug: Sarizotan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan (2 mg/day)
Study: 12889719
Drug: Adapalene solution
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene solution 0.1%
Study: 12889719
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel 0.1%
Study: 12889719
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel 0.05%
Study: 8896124
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg/6 h
Study: 12317784
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate vaginal cream 2%, 5 grams intravaginally at bedtime
Study: 12317784
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole capsules, 500 mg, taken twice daily
Study: 31633778
Drug: BF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF plus CMF group (breastfeeding supplemented with cow's milk formula ≥5 mL/d from the first day of life to 5 months of age)
Study: 15473497
Drug: Concurrent QL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent QL estimates
Study: 12441903
Drug: Applying a
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applying a topical anti-infective cream or ointment or a chlorhexidine-impregnated dressing to the insertion site
Study: 9391222
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine 30 mg orally
Study: 2296931
Drug: Single, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral high dose of vitamin A (n = 65)
Study: 7043710
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release 75 mg capsule b.i.d.
Study: 7043710
Drug: Conventional indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional indomethacin 50 mg capsule t.i.d.
Study: 29543933
Drug: 79.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 79.2 Gy radiation therapy
Study: 29543933
Drug: 70.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70.2 Gy radiation therapy
Study: 26135754
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 25 mg IV for the first week, decreasing to 12.5 mg during the 2nd week until birth
Study: 26135754
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) matching IV treatment
Study: 25288473
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone antagonist (GnRH-ant)
Study: 25288473
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a)
Study: 19859806
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage of All Stars
Study: 19859806
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of higher dosage and higher quality delivery of All Stars
Study: 15550992
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment (Protopic)
Study: 11748093
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg subcutaneous injection)
Study: 8332271
Drug: Enoximone (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (Group C: 0.5 mg/kg bolus and slow infusion at 10 gamma/kg/min)
Study: 2437095
Drug: Acyclovir for
Normalized name: Acyclovir for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir for five days and levamisole twice weekly for three weeks
Study: 24813561
Drug: Macitentan 30
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 30 mg
Study: 22274809
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily gonadotropin administration
Study: 19358785
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of the same medications after acute treatment (mood stabilizer plus antidepressant) for 1 year
Study: 15870414
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose bolus tirofiban plus sirolimus-eluting stenting (n = 87)
Study: 15870414
Drug: Standard-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose abciximab plus bare-metal stenting (n = 88)
Study: 15870414
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose bolus tirofiban plus sirolimus-eluting stenting
Study: 15870414
Drug: Standard-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose abciximab plus bare-metal stenting
Study: 9927831
Drug: Diltiazem (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.15 mg/kg intravenous dose followed by infusion of 3 micrograms/kg/min for 3 hours)
Study: 31116189
Drug: Suturing plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suturing plus leukocyte- and platelet-rich fibrin (L-PRF) plug
Study: 24026598
Drug: Prednisolone +
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone + Pentoxifylline (40 mg prednisolone once a day and 400 mg pentoxifylline 3 times a day for 28 days)
Study: 24026598
Drug: Prednisolone +
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone + Placebo (40 mg prednisolone and matching placebo for 28 days)
Study: 11228275
Drug: Org31540/SR90107A 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org31540/SR90107A 0.75 mg
Study: 11228275
Drug: Org31540/SR90107A 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org31540/SR90107A 1.5 mg
Study: 11228275
Drug: Org31540/SR90107A 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org31540/SR90107A 3.0 mg
Study: 11228275
Drug: Org31540/SR90107A 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org31540/SR90107A 6.0 mg
Study: 11228275
Drug: Org31540/SR90107A 8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org31540/SR90107A 8.0 mg
Study: 11228275
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg every 12 hours
Study: 7815836
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) followed by intensive chemotherapy
Study: 1325513
Drug: Spirapril 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 12.5 mg
Study: 1325513
Drug: Spirapril 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 25 mg
Study: 28695606
Drug: Chrysin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysin 50 mg/day
Study: 28695606
Drug: Chrysin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysin 75 mg/day
Study: 23856657
Drug: Treatment modalities
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modalities (specific modalities not detailed)
Study: 21873253
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol (PEG)
Study: 17030532
Drug: 7-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day antibiotic therapy (n = 34)
Study: 17030532
Drug: 14-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day antibiotic therapy (n = 35)
Study: 17030532
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy for Staphylococcus aureus infection (n = 7)
Study: 17030532
Drug: 14-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day therapy for Staphylococcus aureus infection (n = 7)
Study: 17030532
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy for non-S. aureus infections
Study: 17030532
Drug: 14-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day therapy for non-S. aureus infections
Study: 9595966
Drug: Metrifonate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (0.5 mg/kg, 0.9 mg/kg, or 2.0 mg/kg for 2 weeks followed by maintenance doses of 0.2 mg/kg, 0.3 mg/kg, or 0.65 mg/kg for 10 weeks)
Study: 6340583
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gentamicin sulfate and betamethasone phosphate
Study: 29385007
Drug: Alcohol (1.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.09 g ethanol·kg fat-free body mass)
Study: 28336242
Drug: Pacritinib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib 400 mg once daily
Study: 24077205
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg every 8 hours orally (P group)
Study: 24077205
Drug: Pregabalin 25
Normalized name: pregabalin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 25 mg every 8 hours orally and Imipramine 5 mg every 12 hours orally (P-I group)
Study: 24077205
Drug: Pregabalin 25
Normalized name: pregabalin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 25 mg every 8 hours orally and Mirtazapine 7.5 mg every 12 hours orally (P-M group)
Study: 21430242
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of NSP plus 22 g of RS/d
Study: 21430242
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of NSP
Study: 12907008
Drug: PnCRM7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PnCRM7 vaccine
Study: 11573049
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia and postoperative epidural morphine (group 2)
Study: 11573049
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and postoperative analgesia with parenteral opioids (group 1)
Study: 10095403
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (group B)
Study: 10095403
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (group D)
Study: 10095403
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (group C)
Study: 7845808
Drug: Steroid membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid membrane leads (30 micrograms of dexamethasone)
Study: 3621988
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg daily)
Study: 582710
Drug: Indometacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (150 mg daily)
Study: 21641515
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) treatment (Glucosidorum Tripterygll Totorum tablets and Yishen Juanbi tablets)
Study: 21641515
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (WM) treatment (diclofenec, methotrexate and sulfasalazine)
Study: 21641515
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (WM) treatment
Study: 18359425
Drug: Targeted antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotic therapy (TT)
Study: 18359425
Drug: No targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: No targeted therapy (NoTT)
Study: 16509530
Drug: Daily comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily comprehensive muscle training programme (4-10 minutes daily)
Study: 11009231
Drug: Mexiletine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (maximum dose of 1,350 mg/d)
Study: 9112363
Drug: Isradipine (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0.005 mg/kg)
Study: 8495257
Drug: Pyritinol (PY)
Normalized name: pyritinol
DrugBank: Pyritinol (DB13084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol (PY) 600 mg/day for 1 year
Study: 8495257
Drug: Auranofin (AU)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AU) 6 mg/day for 1 year
Study: 3632393
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone therapy (1.5 mg/kg daily, max 80 mg for six months)
Study: 25634801
Drug: WBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT + sodium nitrite (267 µg/kg/h for 2 hours before each radiation fraction)
Study: 21211975
Drug: De Marco
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De Marco Formula (DMF) combined with conventional therapy (0, 15 ml/kg day i.m. for 10 days, then twice a week until healing or 52 days)
Study: 18264992
Drug: Test procedure
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test procedure for treatment effects among compliers
Study: 14513439
Drug: 500 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 cGy radiation treatment (group A)
Study: 14513439
Drug: 1,000 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 cGy radiation treatment (group B)
Study: 10739327
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 to 20 mg/day)
Study: 27884147
Drug: Standard cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardiac rehabilitation programme + four osteopathic treatments (OT) at weeks 4, 5, 8, and 12 after surgery.
Study: 18071011
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide 160 microg daily for 3 weeks
Study: 18071011
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide 320 microg daily for 3 weeks
Study: 18071011
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide 40 microg daily for 3 weeks
Study: 18071011
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide 80 microg daily for 3 weeks